You are here: Industry Insights > Boehringer Ingelheim

News List

Skyrizi bags positive psoriatic arthritis results pharmatimes
January 08, 2021
AbbVie and Boehringer Ingelheim’s Skyrizi (risankizumab) has scored positive top-line results from two phase III studies in adults with active psoriatic arthritis.
PPF Group Sells Sake in NBE-Therapeutics to Boehringer Ingelheim americanpharmaceuticalreview
December 31, 2020
PPF Group has announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) ...
Boehringer Ingelheim to acquire Labor Dr Merk & Kollegen expresspharma
December 10, 2020
Transaction expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP-based cancer immunology treatments.
Mount Sinai, Boehringer Ingelheim to Evaluate Nintedanib for Fibrosing ILD Following COVID-19 americanpharmaceuticalreview
December 07, 2020
The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
ISMMS, Boehringer Ingelheim to test nintedanib for treating pulmonary fibrosis post-COVID-19 infectio expresspharma
November 23, 2020
The primary endpoint of the study is percent change in forced vital capacity, a measurement of lung function, compared to baseline over six months.
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection prnewswire
November 20, 2020
The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim today announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic pulmonary fibrosis expresspharma
November 10, 2020
Under the License Agreement, Bridge Biotherapeutics will regain all rights to BBT-877.
Boehringer expands oncology partnership with Oxford BioTherapeutics pharmaceutical-technology
October 16, 2020
Boehringer Ingelheim has announced the expansion of its partnership with UK-based Oxford BioTherapeutics (OBT) to discover novel selective targets for strategic cancer indications to deliver treatments for cancer patients.
Schizophrenia Treatment Trial Meets Primary Endpoint americanpharmaceuticalreview
September 21, 2020
Boehringer Ingelheim announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint. The data showed improvement in cognition in stable adult patients with schizophrenia.
Boehringer, Mirati Therapeutics Enter Clinical Collaboration contractpharma
September 18, 2020
To evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page